A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults

Current Medical Research and Opinion

Volumn 30, Issue 8, 2014, Pages 1629-1641

  Citrome, Leslie ^a   Kalsekar, Iftekhar ^b   Baker, Ross A ^c   Hebden, Tony ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aripiprazole; Diabetes; Dyslipidemia; Glucose metabolic disorder; Weight gain

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; ILOPERIDONE; LURASIDONE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

BODY MASS; BODY WEIGHT; BODY WEIGHT DISORDER; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DYSLIPIDEMIA; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPID METABOLISM; METABOLIC DISORDER; MONOTHERAPY; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; WEIGHT GAIN; ADULT; CARBOHYDRATE METABOLISM; CHEMICALLY INDUCED; DRUG EFFECTS; INSULIN RESISTANCE; OBESITY;

ADULT; ANTIPSYCHOTIC AGENTS; CARBOHYDRATE METABOLISM; DIABETES MELLITUS; GLUCOSE METABOLISM DISORDERS; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; LIPID METABOLISM; OVERWEIGHT; PIPERAZINES; QUINOLONES; WEIGHT GAIN;

EID: 84904893870     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.908280     Document Type: Review

References (45)

1. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
2. Citrome L, Jaffe A, Levine J, Martello D. Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997-2004. Psychiatr Serv 2006;57:1132-9
3. Newcomer JW. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with comorbid medical illnesses. J Clin Psychiatry 2009;70(Suppl 3):30-6
4. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(Suppl 1): 1-93
5. Citrome L, Blonde L, Damatarca C. Metabolic issues in patients with severe mental illness. South Med J 2005;98:714-20
6. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947-56
7. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
8. Nasrallah HA. Metabolic findings from the CATIE trial and their relation to tolerability. CNS Spectr 2006;11(7 Suppl 7):32-9
9. Narasimhan M, Masand P. Metabolic syndrome in patients with schizophrenia: CATIE results. Curr Psychiatry Rep 2006;8:213-4
10. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat 2006;2:427-43
11. Citrome LL, Holt RI, Zachry WM, et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007;41:1593-603
12. Spurling RD, Lamberti JS, Olsen D, et al. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007;68:406-9
13. De Hert M, Hanssens L, van Winkel R, et al. A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull 2007;33:823-30
14. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008;69:472-9
15. Lee SY, Park MH, Patkar AA, Pae CU. A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:490-6
16. Guo Z, L'italien GJ, Jing Y, et al. A real-world data analysis of dose effect of second-generation antipsychotic therapy on hemoglobin A1C level. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1326-32
17. Guo X, Fang M, Zhai J, et al. Effectiveness of maintenance treatments with atypical and typical antipsychotics in stable schizophrenia with early stage: 1-year naturalistic study. Psychopharmacology (Berl) 2011;216:475-84
18. Nielsen J, Skadhede S, Correll CU. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patients. Neuropsychopharmacology 2010;35:1997-2004
19. Baker RA, Pikalov A, Tran QV, et al. Atypical antipsychotic drugs and diabetes mellitus in the US Food and Drug Administration Adverse Event database: a systematic Bayesian signal detection analysis. Psychopharmacol Bull 2009;42:11-31
20. Brixner DI, Said Q, Corey-Lisle PK, et al. Naturalistic impact of secondgeneration antipsychotics on weight gain. Ann Pharmacother 2006; 40:626-32
21. Olfson M, Marcus SC, Corey-Lisle P, et al. Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006;163:1821-5
22. Yood MU, DeLorenze G, Quesenberry Jr CP, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent - results from a multisite epidemiologic study. Pharmacoepidemiol Drug Saf 2009;18:791-9
23. DuMouchel W, Fram D, Yang X, et al. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). Ann Clin Psychiatry 2008;20:21-31
24. Kessing LV, Thomsen AF, Mogensen UB, et al. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010;197:266-71
25. Kim SH, Ivanova O, Abbasi FA, et al. Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study. J Clin Psychopharmacol 2007;27:365-8
26. Lee HY, Ham BJ, Kang RH, et al. Trial of aripiprazole in the treatment of firstepisode schizophrenia. Psychiatry Clin Neurosci 2010;64:38-43
27. Takeuchi H, Uchida H, Suzuki T, et al. Changes in metabolic parameters following a switch to aripiprazole in Japanese patients with schizophrenia: one-year follow-up study. Psychiatry Clin Neurosci 2010;64:104-6
28. Ganguli R, Brar J, Garbut R, et al. Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole. Clin Schizophr Relat Psychoses 2011;5:75-9
29. Takahashi H, Oshimo T, Ishigooka J. Efficacy and tolerability of aripiprazole in first-episode drug-naive patients with schizophrenia: an open-label trial. Clin Neuropharmacol 2009;32:149-50
30. Schorr SG, Slooff CJ, Postema R, et al. A 12-month follow-up study of treating overweight schizophrenic patients with aripiprazole. Acta Psychiatrica Scand 2008;118:246-50
31. Kim SH, Nikolics L, Abbasi F, et al. Relationship between body mass index and insulin resistance in patients treated with second generation antipsychotic agents. J Psychiatr Res 2010;44:493-8
32. Kim SW, Shin IS, Kim JM, et al. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia. Clin Neuropharmacol 2009;32:243-9
33. Kwon JS, Jang JH, Kang DH, et al. Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study. Psychiatry Clin Neurosci 2009;63:73-81
34. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996;57(Suppl 11):40-5; discussion 46-52
35. Ulcickas Yood M, Delorenze GN, Quesenberry Jr CP, et al. Association between second-generation antipsychotics and newly diagnosed treated diabetes mellitus: does the effect differ by dose? BMC Psychiatry 2011;11:197
36. De Hert M, Yu W, Detraux J, et al. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder a systematic review and exploratory metaanalysis. CNS Drugs 2012;26:733-59
37. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951-62
38. Morrato EH, Druss B, Hartung DM, et al. Metabolic testing rates in 3 state Medicaid programs after FDA warnings and ADA/APA recommendations for second-generation antipsychotic drugs. Arch Gen Psychiatry 2010; 67:17-24
39. Morrato EH, Newcomer JW, Kamat S, et al. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care 2009;32:1037-42
40. Berkowitz RL, Patel U, Ni Q, et al. The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state. J Clin Psychiatry 2012;73:498-503
41. Essock SM, Covell NH, Davis SM, et al. Effectiveness of switching antipsychotic medications. Am J Psychiatry 2006;163:2090-5
42. Weiden PJ. Switching antipsychotic medications: not enough, too often, or just right? Am J Psychiatry 2011;168:882-4
43. Hasan A, Falkai P, Wobrock T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. World J Biol Psychiatry 2013;14:2-44
44. Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009;70:1041-50
45. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 2010;123:225-33